Chapter 356 |
2023 -- H 5922 Enacted 06/26/2023 |
A N A C T |
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT |
Introduced By: Representatives Hull, Phillips, Diaz, Noret, DeSimone, Fogarty, Abney, and Biah |
Date Introduced: March 01, 2023 |
It is enacted by the General Assembly as follows: |
SECTION 1. Section 21-28-2.08 of the General Laws in Chapter 21-28 entitled "Uniform |
Controlled Substances Act" is hereby amended to read as follows: |
21-28-2.08. Contents of schedules. |
Schedules I through V shall consist of the drugs and other substances, by whatever official |
name, common or usual name, chemical name, or brand name designated, listed in the |
corresponding section, or designated by the director of the department of health pursuant to § 21- |
28-2.01. |
Schedule I |
(a) Schedule I shall consist of the drugs and other substances, by whatever official name, |
common or usual name, chemical name, or brand name designated, listed in this section. |
(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the |
following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers |
whenever the existence of the isomers, esters, ethers, and salts is possible within the specific |
chemical designation: |
(1) Acetylmethadol |
(2) Allylprodine |
(3) Alphacetylmethadol |
(4) Alphameprodine |
(5) Alphamethadol |
(6) Benzethidine |
(7) Betacetylmethadol |
(8) Betameprodine |
(9) Betamethadol |
(10) Betaprodine |
(11) Clonitazene |
(12) Dextromoramide |
(13) Difenoxin |
(14) Diampromide |
(15) Diethylthiambutene |
(16) Dimenoxadol |
(17) Dimepheptanol |
(18) Dimethylthiambutene |
(19) Dioxaphetyl butyrate |
(20) Dipipanone |
(21) Ethylmethylthiambutene |
(22) Etonitazene |
(23) Extoxerdine |
(24) Furethidine |
(25) Hydroxypethidine |
(26) Ketobemidone |
(27) Levomoramide |
(28) Levophenacylmorphan |
(29) Morpheridine |
(30) Noracymethadol |
(31) Norlevorphanol |
(32) Normethadone |
(33) Norpipanone |
(34) Phenadoxone |
(35) Phenampromide |
(36) Phenomorphan |
(37) Phenoperidine |
(38) Piritramide |
(39) Proheptazine |
(40) Properidine |
(41) Propiram |
(42) Racemoramide |
(43) Trimeperidone |
(44) Tilidine |
(45) Alpha-methylfentanyl |
(46) Beta-hydroxy-3-methylfentanyl other names: |
N-[1-(2hydroxy-2-phenethyl)-3-methyl-4piperidingyl]-Nphenylpropanamide |
(47) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- |
phenylpropanamide) |
(48) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its optical, positional, and |
geometric isomers, salts and salts of isomers (Other names: acetyl fentanyl) |
(49) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenyl propionamide |
(Other names: beta-hydroxythiofentanyl) |
(50) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide (Other names: Butyryl fentanyl) |
(51) N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (Other names: Furanyl |
fentanyl) |
(52) 3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide (Other names: AH- |
7921) |
(53) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (Other names: |
U-47700) |
(54) 3-Methylbutyrfentanyl (Other names: 3-MBF) |
(55) 4-Fluorobutyrfentanyl (Other names: 4-FBF, p-FBF) |
(56) 4-Phenylfentanyl |
(57) 4-Methoxybutyrfentanyl (Other names: 4-MeO-BF) |
(58) Acrylfentanyl (Other names: acryloyfentanyl) |
(59) Lofentanyl |
(60) N-Methylcarfentanyl |
(61) Ocfentanyl (INN, A-3217) |
(63) 4-methoxymethylfentanyl (Other names: R-30490) |
(64) 1-cyclohexyl-4-(1,2 diphenylethyl)piperazine) (Other names: MT-45, IC-6) |
(c)(b) Opium Derivatives. Unless specifically excepted or unless listed in another schedule, |
any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the |
existence of the salts, isomers, and salts of isomers is possible within the specific chemical |
designation: |
(1) Acetorphine |
(2) Acetyldihydrocodeine |
(3) Benzylmorphine |
(4) Codeine methylbromide |
(5) Codeine-N-Oxide |
(6) Cyprenorphine |
(7) Desomorphine |
(8) Dihydromorphine |
(9) Etorphine (Except hydrochloride salt) |
(10) Heroin |
(11) Hydromorphinol |
(12) Methyldesorphine |
(13) Methylihydromorphine |
(14) Morphine methylbromide |
(15) Morphine methylsulfonate |
(16) Morphine-N-Oxide |
(17) Myrophine |
(18) Nococodeine |
(19) Nicomorphine |
(20) Normorphine |
(21) Pholcodine |
(22) Thebacon |
(23) Drotebanol |
(d)(c) Hallucinogenic Substances. Unless specifically excepted or unless listed in another |
schedule, any material, compound, mixture, or preparation that contains any quantity of the |
following hallucinogenic substances, or that contains any of its salts, isomers, and salts of isomers |
whenever the existence of the salts, isomers, and salts of isomers is possible within the specific |
chemical designation (for purposes of this subsection only, the term “isomer” includes the optical, |
position, and geometric isomers): |
(1) 3, 4-methylenedioxy amphetamine |
(2) 5-methoxy-3, 4-methylenedioxy amphetamine |
(3) 3, 4, 5-trimethoxy amphetamine |
(4) Bufotenine |
(5) Diethyltryptamine |
(6) Dimethyltryptamine |
(7) 4-methyl 2, 5-dimethoxyamphetamine |
(8) Ibogaine |
(9) Lysergic acid diethylamide |
(10) Marihuana |
(11) Mescaline |
(12) Peyote. Meaning all parts of the plant presently classified botanically as Lophophora |
Williamsii Lemair whether growing or not; the seeds of the plant; any extract from any part of the |
plant; and any compound, manufacture, salt, derivative, mixture, or preparation of the plant, its |
seeds or extracts. |
(13) N-ethyl-3-piperidyl benzilate |
(14) N-methyl-3-piperidyl benzilate |
(15) Psilocybin |
(16) Psilocyn |
(17) Tetrahydrocannabinols. Synthetic equivalents of the substances contained in the plant, |
or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their |
isomers with similar chemical structure and pharmacological activity such as the following: delta |
1 cis or trans tetrahydrocannabinol, and their optical isomers. Delta 6 cis or trans |
tetrahydrocannabinol and their optical isomers. Delta 3, 4 cis or trans tetrahydrocannabinol and |
their optical isomer. (Since nomenclature of these substances is not internationally standardized, |
compounds of these structures, regardless of numerical designation of atomic positions covered). |
(18) Thiophene analog of phencyclidine. 1-(1-(2 thienyl) cyclo-hexyl) pipiridine: 2- |
Thienyl analog of phencyclidine: TPCP |
(19) 2,5 dimethoxyamphetamine |
(20) 4-bromo-2,5-dimethoxyamphetamine, 4-bromo-2,5-dimethoxy-alpha- |
methylphenethyamine: 4-bromo-2,5-DMA |
(21) 4-methoxyamphetamine-4-methoxy-alpha-methylphenethylaimine: |
paramethoxyamphetamine: PMA |
(22) Ethylamine analog of phencyclidine. N-ethyl-1-phenylcyclohexylamine, (1- |
phenylcyclohexyl) ethylamine, N-(1-phenylcyclophexyl) ethylamine, cyclohexamine, PCE |
(23) Pyrrolidine analog of phencyclidine. 1-(1-phencyclohexyl)-pyrrolidine PCPy, PHP |
(24) Parahexyl; some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- |
trimethyl-6H-dibenz o (b,d) pyran: Synhexyl. |
(25) Salvia Divinorum (Salvinorin A or Divinorin A), meaning any extract from any part |
of the plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall |
not mean the unaltered plant. |
(26) Datura stamonium (jimsom weed or datura), meaning any extract from any part of the |
plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall not mean |
the unaltered plant. |
(e)(d) Depressants. Unless specifically excepted or unless listed in another schedule, any |
material, compound, mixture, or preparation that contains any quantity of the following substances |
having a depressant effect on the central nervous system, including its salts, isomers, and salts of |
isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the |
specific chemical designation: |
(1) Mecloqualone. |
(2) Methaqualone. |
(3) 3-methyl fentanyl (n-(3methyl-1(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. |
(4) 3,4-methyl-enedioxymethamphetamine (MDMA), its optical, positional, and geometric |
isomers, salts, and salts of isomers. |
(5) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts, and salts |
of isomers. |
(6) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP), its optical isomers, salts, |
and salts of isomers. |
(7) N-(1-(1-methyl-2-phenyl)ethyl-4-piperidyl)-N-phenyl-acetamide (acetyl- |
alphamethylfentanyl), its optical isomers, salts, and salts of isomers. |
(8) N-(1-(1-methyl-2(2-thienyl)ethyl-4-piperidyl)-N-phenylpropanami de (alpha- |
methylthiofentanyl), its optical isomers, salts, and salts of isomers. |
(9) N-(1-benzyl-piperidyl)-N-phenylpropanamide (benzyl-fentanyl), its optical isomers, |
salts, and salts of isomers. |
(10) N-(1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenyl-propanamid e (beta- |
hydroxyfentanyl), its optical isomers, salts, and salts of isomers. |
(11) N-(3-methyl-1(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenylpro panamide (beta- |
hydroxy-3-methylfentanyl), its optical and geometric isomers, salts, and salts of isomers. |
(12) N-(3-methyl)-1-(2-(2-thienyl)ethyl-4-piperidyl)-N-phenylpro-panamide (3- |
methylthiofentanyl), its optical and geometric isomers, salts, and salts of isomers. |
(13) N-(1-2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its |
optical isomers, salts, and salts of isomers. |
(14) N-(1-(2(2-thienyl)ethyl-4-piperidyl-N-phenylpropanamide (thiofentanyl), its optical |
isomers, salts, and salts of isomers. |
(15) N-[1-(2-phenylethyl)-4-piperidyl]-N-(4-fluorophenyl)-propanamid e (para- |
fluorofentanyl), its optical isomers, salts, and salts of isomers. |
(16) Gamma hydroxybutyrate, HOOC-CH2-CH2-CH2OH, its optical, position, or |
geometric isomers, salts, and salts of isomers. |
(17) Etizolam. |
(18) Flubromazolam. |
(f)(e) Stimulants. Unless specifically excepted or unless listed in another schedule, any |
material, compound, mixture, or preparation that contains any quantity of the following substances |
having a stimulant effect on the central nervous system, including its salts, isomers, and salts of |
isomers: |
(1) Fenethylline |
(2) N-ethylamphetamine |
(3) 4-methyl-N-methylcathinone (Other name: mephedrone) |
(4) 3,4-methylenedioxy-N-methlycathinone (Other name: methylone) |
(5) 3,4-methylenedioxypyrovalerone (Other name: MDPV) |
(g) Any material, compound, mixture, or preparation that contains any quantity of the |
following substances: |
(1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497) |
(2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol |
(cannabicyclohexanol and CP-47,497 c8 homologue) |
(3) 1-Butyl-3-(1 naphthoyl)indole, (JWH-073) |
(4) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) |
(5) 1-Pentyl-3-(1-napthoyl)indole, (JWH-018 and AM678) |
(h)(gf) Synthetic cannabinoids or piperazines. Unless specifically excepted, any chemical |
compound which is not approved by the United States Food and Drug Administration or, if |
approved, which is not dispensed or possessed in accordance with state and federal law, that |
contains Benzylpiperazine (BZP); Trifluoromethylphenylpiperazine (TFMPP); 1,1- |
Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-naphthoyl) indole; 1- |
Pentyl-3-(1-naphthoyl) indole; dexanabinol (HU-211); or any compound in the following structural |
classes: |
(1) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with |
substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
group, whether or not further substituted in the indole ring to any extent and whether or not |
substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
limited, to JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, and AM- |
2201; |
(2) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with |
substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
group whether or not further substituted in the indole ring to any extent and whether or not |
substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
limited to, JWH-167, JWH-250, JWH-251, and RCS-8; |
(3) Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with |
substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
group whether or not further substituted in the indole ring to any extent and whether or not |
substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
limited, to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; |
(4) Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol |
structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
group whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural |
class include, but are not limited to, CP 47,497 and its C8 homologue (cannabicyclohexanol); |
(5) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl) |
methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4- |
morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and |
whether or not substituted in the naphthyl ring to any extent. Examples of this structural class |
include, but are not limited to, JWH-175, JWH-184, and JWH-185; |
(6) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure with |
substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
group whether or not further substituted in the pyrrole ring to any extent and whether or not |
substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
limited, to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; |
(7) Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl)indene |
structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
group whether or not further substituted in the indene ring to any extent and whether or not |
substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
limited to, JWH-176; or |
(8) Any other synthetic cannabinoid or piperazine which is not approved by the United |
States Food and Drug Administration or, if approved, which is not dispensed or possessed in |
accordance with state and federal law. |
(ih) Synthetic cathinones. Unless specifically excepted, any chemical compound which is |
not approved by the United States Food and Drug Administration or, if approved, which is not |
dispensed or possessed in accordance with state and federal law, not including bupropion, |
structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, |
naphthyl, or thiophene ring systems, whether or not the compound is further modified in one or |
more of the following ways: |
(1) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, |
haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by |
one or more other univalent substituents. Examples of this class include, but are not limited to, 3,4- |
Methylenedioxycathinone (bk-MDA); |
(2) By substitution at the 3-position with an acyclic alkyl substituent. Examples of this |
class include, but are not limited to, 2-methylamino-1-phenylbutan-1-one (buphedrone); |
(3) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or |
methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. |
Examples of this class include, but are not limited to, Dimethylcathinone, Ethcathinone, and α- |
Pyrrolidinopropiophenone (α-PPP); or |
(4) Any other synthetic cathinone which is not approved by the United States Food and |
Drug Administration or, if approved, is not dispensed or possessed in accordance with state or |
federal law. Examples of this class include, but are not limited to, Ephylone and Pentylone. |
Schedule II |
(a) Schedule II shall consist of the drugs and other substances, by whatever official name, |
common or usual name, chemical name, or brand name designated, listed in this section. |
(b) Substances, vegetable origin, or chemical synthesis. Unless specifically excepted or |
unless listed in another schedule, any of the following substances whether produced directly or |
indirectly by extraction from substances of vegetable origin, or independently by means of |
chemical synthesis, or by a combination of extraction and chemical synthesis: |
(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or |
opiate excluding naloxone and its salts, and excluding naltrexone and its salts, but including the |
following: |
(i) Raw opium |
(ii) Opium extracts |
(iii) Opium fluid extracts |
(iv) Powdered opium |
(v) Granulated opium |
(vi) Tincture of opium |
(vii) Etorphine hydrochloride |
(viii) Codeine |
(ix) Ethylmorphine |
(x) Hydrocodone |
(xi) Hydromorphone |
(xii) Metopon |
(xiii) Morphine |
(xiv) Oxycodone |
(xv) Oxymorphone |
(xvi) Thebaine |
(2) Any salt, compound, derivative, or preparation that is chemically equivalent or identical |
with any of the substances referred to in subdivision (1) of this subsection, except that these |
substances shall not include the isoquinoline alkaloids of opium. |
(3) Opium poppy and poppy straw. |
(4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any |
salt, compound, derivative, or preparation that is chemically equivalent or identical with any of |
these substances, except that the substances shall not include decocainized coca leaves or extraction |
of coca leaves, which extractions do not contain cocaine or ecgonine. |
(5) Concentrate of poppy straw (the crude extract of poppy straw in liquid, solid, or powder |
form that contains the phenanthrine alkaloids of the opium poppy). |
(c)(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the |
following opiates, including its isomers, esters, ethers, salts; and salts of isomers, esters, and ethers |
whenever the existence of the isomers, esters, ethers, and salts is possible within the specific |
chemical designation: |
(1) Alphaprodine |
(2) Anileridine |
(3) Bezitramide |
(4) Dihydrocodeine |
(5) Diphenoxylate |
(6) Fentanyl |
(7) Isomethadone |
(8) Levomethorphan |
(9) Levorphanol |
(10) Metazocine |
(11) Methadone |
(12) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane |
(13) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic |
acid |
(14) Pethidine |
(15) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine |
(16) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate |
(17) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid |
(18) Phenaxocine |
(19) Piminodine |
(20) Racemethorphan |
(21) Racemorphan |
(22) Bulk Dextropropoxyphene (non-dosage forms) |
(23) Suffentanil |
(24) Alfentanil |
(25) Levoalphacetylmethadol |
(26) Carfentanil |
(27) Remifentanil |
(d)(c) Stimulants. Unless specifically excepted or unless listed in another schedule, any |
material, compound, mixture, or preparation that contains any quantity of the following substances |
having a stimulant effect on the central nervous system: |
(1) Amphetamine, its salts, optical isomers, and salts of its optical isomers. |
(2) Methamphetamine, its salts, and salts of its isomers. |
(3) Phenmetrazine and its salts. |
(4) Methylphenidate. |
(e)(d) Depressants. Unless specifically excepted or unless listed in another schedule, any |
material, compound, mixture, or preparation that contains any quantity of the following substances |
having a depressant effect on the central nervous system, including its salts, isomers, and salts of |
isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the |
specific chemical designation: |
(1) Amobarbital |
(2) Glutethimide |
(3) Methyprylon |
(4) Pentobarbital |
(5) Phencyclidine |
(6) Secobarbital |
(7) Phencyclidine immediate precursors: |
(i) 1-phencyclohexylamine |
(ii) 1-piperidinocyclohexane-carbonitrile (PCC) |
(8) Immediate precursor to amphetamine and methamphetamine: Phenylacetone. Some |
other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzone ketone. |
Schedule III |
(a) Unless specifically excepted or unless listed in another schedule, any material, |
compound, mixture, or preparation that contains any quantity of the following substances having a |
depressant effect on the central nervous system: |
(1) Any substance that contains any quantity of a derivative of barbituric acid or any salt |
of a derivative of barbituric acid. |
(2) Chlorhexadol |
(3) Lysergic acid |
(4) Lysergic acid amide |
(5) Sulfondiethylmethane |
(6) Sulfonethylmethane |
(7) Sylfonmethane |
(8) Any compound, mixture, or preparation containing amobarbital, secobarbital, |
pentobarbital, or any salt of them and one or more other active medicinal ingredients that are not |
listed in any schedule. |
(9) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or |
any salt of any of these drugs and approved by the Food and Drug Administration for marketing |
only as a suppository. |
(10) Ketamine, its salts, isomers, and salts of isomers. (Some other names for ketamine: |
(+)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone). |
(b) Unless specifically excepted or unless listed in another schedule, any material, |
compound, mixture, or preparation containing limited quantities of any of the following narcotic |
drugs, or any salts of them: |
(1) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with an equal |
or greater quantity of an isoquinoline alkaloid of opium. |
(2) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or |
more active, nonnarcotic ingredients in recognized therapeutic amounts. |
(3) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
a fourfold or greater quantity of an isoquinoline alkaloid of opium. |
(4) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
(5) Not more than one and eight tenths grams (1.8 gms.) of dihydrocodeine per one hundred |
milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or |
more active nonnarcotic ingredients in recognized therapeutic amounts. |
(6) Not more than three hundred milligrams (300 mgs.) of ethylmorphine per one hundred |
milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with one or |
more active nonnarcotic ingredients in recognized therapeutic amounts. |
(7) Not more than five hundred milligrams (500 mgs.) of opium per one hundred milliliters |
(100 mls.) or per one hundred grams (100 gms.) or not more than twenty-five milligrams (25 mgs.) |
per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
(8) Not more than fifty milligrams (50 mgs.) of morphine per one hundred milliliters (100 |
mls.) per one hundred grams (100 gms.) with one or more active, nonnarcotic ingredients in |
recognized therapeutic amounts. |
(c) Stimulants. Unless specifically excepted or listed in another schedule, any material, |
compound, mixture, or preparation that contains any quantity of the following substances having a |
stimulant effect on the central nervous system, including its salts, isomers, and salts of the isomers |
whenever the existence of the salts of isomers is possible within the specific chemical designation: |
(1) Benzphetamine |
(2) Chlorphentermine |
(3) Clortermine |
(4) Mazindol |
(5) Phendimetrazine |
(d) Steroids and hormones. Anabolic steroids (AS) or human growth hormone (HGH), |
excluding those compounds, mixtures, or preparations containing an anabolic steroid that because |
of its concentration, preparation, mixture, or delivery system, has no significant potential for abuse, |
as published in 21 C.F.R. § 1308.34, including, but not limited to, the following: |
(1) Chorionic gonadotropin, except for veterinary use and when that use is approved by the |
Food and Drug Administration. |
(2) Clostebol |
(3) Dehydrochlormethyltestosterone |
(4) Ethylestrenol |
(5) Fluoxymesterone |
(6) Mesterolone |
(7) Metenolone |
(8) Methandienone |
(9) Methandrostenolone |
(10) Methyltestosterone |
(11) Nandrolone decanoate |
(12) Nandrolone phenpropionate |
(13) Norethandrolone |
(14) Oxandrolone |
(15) Oxymesterone |
(16) Oxymetholone |
(17) Stanozolol |
(18) Testosterone propionate |
(19) Testosterone-like related compounds |
(20) Human Growth Hormone (HGH) |
(e) Hallucinogenic substances. |
(1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in U.S. |
Food and Drug Administration-approved drug product. (Some other names for dronabinol: (6aR- |
trans)-6a, 7, 8, 10a-tetrahydro-6, 6, 9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)-delta- |
9(trans)-tetrahydrocannabinol.) |
Schedule IV |
(1) Barbital. |
(2) Chloral betaine |
(3) Chloral hydrate |
(4) Ethchrovynol |
(5) Ethinamate |
(6) Methohexital |
(7) Meprobamate |
(8) Methylphenobarbital |
(9) Paraldehyde |
(10) Petrichloral |
(11) Phenobarbital |
(12) Fenfluramine |
(13) Diethylpropion |
(14) Phentermine |
(15) Pemoline (including organometallic complexes and chelates thereof). |
(16) Chlordiazepoxide |
(17) Clonazepam |
(18) Clorazepate |
(19) Diazepam |
(20) Flurazepam |
(21) Mebutamate |
(22) Oxazepam |
(23) Unless specifically excepted or unless listed in another schedule, any material, |
compound, mixture, or preparation that contains any quantity of the following substances, including |
its salts: |
Dextropropoxyphene(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propronox |
ybutane). |
(24) Prazepam |
(25) Lorazepam |
(26) Not more than one milligram (1 mg.) of difenoxin and not less than twenty-five (25) |
micrograms of atropine sulfate per dosage unit. |
(27) Pentazocine |
(28) Pipradrol |
(29) SPA (-)-1-dimethylamino-1, 2-diphenylethane |
(30) Temazepam |
(31) Halazepam |
(32) Alprazolam |
(33) Bromazepam |
(34) Camazepam |
(35) Clobazam |
(36) Clotiazepam |
(37) Cloxazolam |
(38) Delorazepam |
(39) Estazolam |
(40) Ethyl Ioflazepate |
(41) Fludizaepam |
(42) Flunitrazepam |
(43) Haloxazolam |
(44) Ketazolam |
(45) Loprazolam |
(46) Lormetazepam |
(47) Medazepam |
(48) Nimetazepam |
(49) Nitrazepam |
(50) Nordiazepam |
(51) Oxazolam |
(52) Pinazepam |
(53) Tetrazepam |
(54) Mazindol |
(55) Triazolam |
(56) Midazolam |
(57) Quazepam |
(58) Butorphanol |
(59) Sibutramine |
(60) Tramadol |
(61) Zolpidem |
Schedule V |
(a) Any compound, mixture, or preparation containing any of the following limited |
quantities of narcotic drugs, which shall include one or more non-narcotic active medicinal |
ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable |
medicinal qualities other than those possessed by the narcotic drug alone: |
(1) Not more than two hundred milligrams (200 mgs.) of codeine per 100 milliliters (100 |
mls.) or per one hundred grams (100 gms.). |
(2) Not more than one hundred milligrams (100 mgs.) of dihydrocodeine per 100 milliliters |
(100 mls.) or per one hundred grams (100 gms.). |
(3) Not more than one hundred milligrams (100 mgs.) of ethylmorphine per 100 milliliters |
(100 mls.) or per one hundred grams (100 gms.). |
(4) Not more than two and five tenths milligrams (2.5 mgs.) of diphenixylate and not less |
than twenty-five (25) micrograms of atropine sulfate per dosage unit. |
(5) Not more than one hundred milligrams (100 mgs.) of opium per one hundred milliliters |
(100 mls.) or per one hundred grams (100 gms.). |
(b) Not more than five tenths milligrams (0.5 mgs.) of difenoxin and not less than twenty- |
five (25) micrograms of atropine sulfate per dosage unit. |
(c) Buprenorphine |
(d) Unless specifically exempted or excluded or unless listed in another schedule, any |
material, compound, mixture, or preparation that contains any quantity of the following substances |
having a stimulant effect on the central nervous system, including its salts, isomers, and salts of |
isomers: |
(1) Propylhexedrine (except as benzedrex inhaler) |
(2) Pyrovalerone. |
(e) Xylazine HCL |
SECTION 2. This act shall take effect upon passage. |
======== |
LC002079 |
======== |